Azitra, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Azitra, Inc. (AZTR) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-02-27
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $0.00.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.50K, a 98.91% decline from fiscal 2023.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $686.00K, a 141.55% increase from fiscal 2022.
- Azitra, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $284.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $7.50K derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $7.50K derived: sum of 3 quarters · filed 2026-02-27 | $7.50K 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $7.50K derived: sum of 2 quarters · filed 2025-11-12 | $7.50K 10-Q · filed 2025-11-12 | $97.50K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.50K 10-Q · filed 2025-08-11 | $7.50K 10-Q · filed 2025-08-11 | $97.50K derived: sum of 3 quarters · filed 2025-08-11 | $408.20K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $90.00K derived: sum of 2 quarters · filed 2025-02-24 | $400.70K derived: sum of 3 quarters · filed 2025-02-24 | $572.70K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $400.70K derived: sum of 2 quarters · filed 2025-02-24 | $572.70K derived: sum of 3 quarters · filed 2025-02-24 | $686.00K 10-K · filed 2025-02-24 |
| 2023-09-30 | $310.70K 10-Q · filed 2024-11-12 | $482.70K derived: sum of 2 quarters · filed 2024-11-12 | $596.00K 10-Q · filed 2024-11-12 | $626.50K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $172.00K 10-Q · filed 2024-08-12 | $285.30K 10-Q · filed 2024-08-12 | $315.80K derived: sum of 3 quarters · filed 2024-08-12 | $364.30K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $113.30K 10-Q · filed 2024-05-09 | $143.80K derived: sum of 2 quarters · filed 2024-05-09 | $192.30K derived: sum of 3 quarters · filed 2024-05-09 | $277.30K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $30.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $79.00K derived: sum of 2 quarters · filed 2024-03-15 | $164.00K derived: sum of 3 quarters · filed 2024-03-15 | $284.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | $48.50K 10-Q · filed 2023-11-14 | $133.50K derived: sum of 2 quarters · filed 2023-11-14 | $253.50K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $85.00K 10-Q · filed 2023-08-14 | $205.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |